Skip to main content
Quratis Inc. logo

Quratis Inc. — Investor Relations & Filings

Ticker · 348080 ISIN · KR7348080003 KO Manufacturing
Open in API
Filings indexed 238 across all filing types
Latest filing 2026-05-15 Proxy Solicitation & In…
Country KR South Korea
Listing KO 348080

About Quratis Inc.

https://www.quratis.com

Quratis Inc. is a biopharmaceutical company specializing in the research and development of vaccines and therapeutic agents for infectious diseases. The company's lead pipeline candidate is QTP101, a novel tuberculosis (TB) vaccine developed for adolescents and adults, an area with significant unmet medical needs. Quratis operates its own GMP-certified manufacturing facility, enabling the production of various biologics such as DNA plasmids, RNA, and proteins to support its development programs. The company is advancing the global commercialization of its TB vaccine through strategic partnerships and technology transfers, with notable progress in key Asian markets.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a notice of convening the 11th Extraordinary General Meeting of Shareholders (“주주총회소집공고”), setting out date, venue, agenda items for shareholder approval, and extensive background information (director activities, related‐party transactions, business overview, etc.). It is not a financial report (no financial statements), not an annual or interim report, and not merely a brief announcement. It is clearly the information/proxy materials provided to shareholders to solicit votes at a meeting, which corresponds to “Proxy Solicitation & Information Statement.”
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is a full Korean "분기보고서" covering the company’s first quarter (January 1 to March 31, 2026) with detailed business overview, corporate history, governance changes, capital movements, share information, and pipeline descriptions. It is not merely an announcement or press release but contains substantive financial and operational content typical of a quarterly report. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
[기재정정]주요사항보고서(감자결정)
Regulatory Filings
2026-05-06 Korean
소속부변경
Regulatory Filings
2026-04-30 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 85% confidence The document is a regulatory announcement disclosing the conclusion of a single sale and supply contract (임상 의약품 제조 위수탁 계약) with 주요 내용 such as contract counterpart, period, and payment terms. It does not represent an annual or interim financial report, earnings release, capital financing update, M&A transaction, insider dealing, dividend notice, proxy statement, or specific AGM material. There is no indication of a detailed investor presentation or management discussion. Therefore, it is a general regulatory filing reporting a material contract and falls under the fallback category of Regulatory Filings (RNS).
2026-04-23 Korean
주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal notice of convening an Extraordinary General Meeting (임시주주총회소집결의), specifying date, time, venue, record date, board resolution date, and agenda (proposal for capital reduction to cover losses). It is not the voting results, nor a summary of financial results, but rather a notice/solicitation for shareholders to attend and vote at the meeting. According to the filing definitions, materials sent to shareholders to request votes for meetings fall under Proxy Solicitation & Information Statement (Code: PSI).
2026-04-14 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.